PROKIDNEY CORP CLASS A (PROK)
Health Care · biotechnology · NASDAQ
ProKidney is a biotech company developing a first-in-class, personalized autologous cell therapy to preserve kidney function in patients with advanced chronic kidney disease and diabetes.
What PROKIDNEY CORP CLASS A does
ProKidney is a clinical-stage biotechnology company developing rilparencel, an autologous cell therapy designed to preserve kidney function in patients with advanced chronic kidney disease (CKD) and type 2 diabetes. By utilizing a patient's own kidney cells, the therapy aims to stabilize or attenuate the decline of the estimated glomerular filtration rate (eGFR) and delay the need for dialysis or transplantation without the requirement for long-term immunosuppression.
Recent developments
In August 2026, the company completed enrollment of the patient population required for the accelerated approval efficacy analysis of its Phase 3 PROACT 1 trial, with topline results for the surrogate endpoint expected in Q2 2027. Additionally, Kenneth Locke was appointed as Chief Technical Officer to oversee manufacturing and supply chain operations.
From PROKIDNEY CORP CLASS A's filing of 2026-08-10.
Themes: regenerative medicine, cell therapy, chronic kidney disease, diabetes
Fundamentals
- Price$1.66 as of 2026-10-08 close
- Market cap$502M as of 2026-08-10 (share count; price 2026-10-08)
- 1-year return-49.1% 2025-10-08 close $3.26 → 2026-10-08 close $1.66
- P/En/a negative earnings
- Debt / equity5.40 as of 2026-09-02
- Revenue growth (YoY)+190.5% as of 2026-09-02
- Beta2.42 as of 2026-09-02
- Last reported earnings2026-08-10 SEC EDGAR Form 8-K (Item 2.02)
How PROK compares in its sector
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How PROKIDNEY CORP CLASS A looks technically
PROKIDNEY CORP CLASS A (PROK) is trading 12.5% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 158 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 15, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 48, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 2 trading days ago. It is 52.3% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 12.5% below its 200-day average, the long-term trend line — a long-term downtrend | -12.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $1.68 | $1.68 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $1.90 | $1.90 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 1.76. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 158 trading days ago — a "death cross", a bearish long-term signal | 158 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 15, below the 25 that marks a real trend) | 15.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 48, neither overbought (above 70) nor oversold (below 30) | 47.8 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($1.53 to $1.91) — its "stochastic" reading is 34 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 34.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 18 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $3.48 | $3.48 |
|---|---|---|
| From the 52-week high | it is 52.3% below its 52-week high (its highest price of the past year) | -52.3% |
| Above the 52-week low | it is 27.7% above its 52-week low (its lowest price of the past year) | +27.7% |
| Below the 52-week high | it is 52.3% below its highest point of the past year | 52.3% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day low about 39 trading days ago | 39 sessions |
| All-time high | its highest closing price on record is $14.19 (set on 2023-03-13) | $14.19 |
| Given back of the 52-week move | over the past year its closes ranged ($1.33 to $3.30), and it has recovered roughly a quarter of its fall from last year’s high — 17% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $2.55 to $2.61. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 16.8% |
| From the all-time high | it is 88.3% below its all-time high | -88.3% |
| Nearest price level | it is trading 1.1% above a support level at $1.64 — a price it turned at twice since 2024-10-23, most recently on 2026-06-25. Since 2024-10-08 it has 5 such levels below the current price and 9 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.1% |
| All-time low | its lowest closing price on record is $0.46 (set on 2025-04-09) | $0.46 |
| Above the all-time low | it is 260.9% above its all-time low | +260.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 33rd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1103 between its high and its low — about 6.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1103 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $1.51 and $1.91 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $1.51 – $1.71 – $1.91 |
| Typical daily range (% of price) | its price moves about 6.6% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.6% |
| Stretch from the 200-day average | it is trading 2.2 daily ranges below its 200-day average price (12.5% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.2 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.76× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a doji | 4 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 4 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-10-08 1.3% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.3% |
|---|---|---|
| Gap filled | a 2.5% gap down opened on 2026-10-07 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 1 session ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 17.6 percentage points (the stock lost 16.6% while the market gained 1.0%) | -17.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 13.6 percentage points (the stock lost 9.8% while the market gained 3.8%) | -13.6% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 25.7 percentage points (the stock lost 8.3% while the market gained 17.5%) | -25.7% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 64.1 percentage points (the stock lost 49.1% while the market gained 15.0%) | -64.1% |
Signal agreement
2
| Bullish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bullish state — these describe past price behaviour, not a forecast | 0 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, lagging the market over 6 months — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 8.6% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 10% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $1.85 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | -10.2% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% below the average price paid since it last reported on 2026-08-10 (its 10-Q), so the typical buyer over that stretch is under water. That average is $1.71 — a volume-weighted average of daily closes over 43 sessions, not a true tick-by-tick VWAP. | -3.1% |
Price levels it has turned at before
PROK last closed at $1.66 on 2026-10-08. Since 2024-10-08 it has turned at 5 prices below its last close and 9 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $1.64 | Support | 1.1% below the last close | turned there twice · 2024-10-23 to 2026-06-25 |
| $1.75 | Resistance | 5.7% above the last close | turned there twice · 2026-04-29 to 2026-10-01 |
| $1.53 | Support | 7.5% below the last close | turned there twice · 2026-05-19 to 2026-09-28 |
| $1.50 | Support | 9.9% below the last close | turned there twice · 2024-11-04 to 2024-11-19 |
| $1.97 | Resistance | 18.7% above the last close | turned there twice · 2026-06-02 to 2026-09-18 |
| $2.05 | Resistance | 23.7% above the last close | turned there three times · 2025-11-26 to 2026-01-21 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $1.76.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 3 trading days, since 2026-10-06.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · trendless / choppy (low ADX) · lagging the market · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$6.25 range $1.00 – $12.00; median $5.75
Analyst estimates, as of 2026-10-04. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for PROK
- Consensus EPS estimate-$0.1398 next reporting period, as of 2026-10-04
- Estimate change, 30 days-$0.00175 from -$0.138, on 2026-08-30, 35-day window
- Readings revised upward14% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Substantial doubt regarding the company's ability to continue as a going concern due to recurring losses and insufficient cash to fund operations for the next 12 months.","Clinical trial success is uncertain, and failure to meet primary endpoints in phase 3 studies would materially harm the business."]
What changed in the latest 10-Q
AI-assisted comparison of PROK's 10-Q filed 2026-05-15 against the prior one filed 2025-11-10.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-15) added reference to 'and its subsidiaries' after ProKidney Corp in opening line
- Newer filing added specific date of Form 10-K filing: 'March 18, 2026'
- Newer filing describes rilparencel as 'late-clinical-stage' rather than 'clinical-stage' biotechnology company
- Newer filing added detailed description: 'Rilparencel is a product that includes autologous Selected Renal Cells (SRC) prepared from a patient's own (autologous) kidney cells' with explanation of formulation and reinjection procedure
- Newer filing added statement: 'Because rilparencel is a personalized product composed of cells prepared from a patient's own kidney, there is no need for treatment with immunosuppressive therapies that are required during a patient's lifetime when a patient receives a kidney transplant from another (allogeneic) donor'
- Newer filing added section on domestication: 'Effective July 1, 2025, ProKidney Corp. completed a domestication process through which it changed its jurisdiction of incorporation from the Cayman Islands to the State of Delaware'
- Newer filing added explanation of presentation conventions for stock and subsidiary names post-Domestication
- Newer filing describes PROACT 1 study protocol as amended to focus on 'Stage 4 CKD (estimated glomerular filtration rate (eGFR) between 20 and 30 mL/min/1.73m²) and late Stage 3b CKD (eGFR between 30 and 35 mL/min/1.73m² with accompanying albuminuria UACR between 300 and 5000 mg/g)'
- Newer filing specifies study locations: 'clinical centers in the United States, Mexico, and Taiwan'
- Newer filing specifies rilparencel dose: '3x10⁶ cells/g-KW est'
- Newer filing states: 'The efficacy analysis set is expected to contain approximately 320 patients and will include all patients with at least six months of follow-up after first injection'
- Newer filing adds: 'We anticipate topline data readout of the confirmatory endpoint (composite time-to-event) in the second half of 2029'
- Newer filing mentions revenue from 'leasing activities associated with existing lease agreements assumed through the acquisition of two buildings in Winston-Salem'
- Removed:
- Older filing (2025-11-10) stated company was 'founded in 2015 after a decade of research'—removed in newer filing
- Older filing stated rilparencel 'also known as REACT®'—removed in newer filing
- Older filing described study as 'sham controlled safety and efficacy study'—newer filing specifies 'bi-lateral kidney dosing, sham controlled arm, efficacy and safety study'
- Older filing stated total planned enrollment was 'approximately 685 subjects'—newer filing states 'approximately 470 patients' with 'targeted enrollment'
- Older filing detailed complex UACR criteria for different eGFR ranges—newer filing provides simpler unified criteria 'UACR between 300 and 5000 mg/g'
- Older filing stated injections delivered 'one in each kidney'—newer filing states 'both kidneys' and specifies 'two injections of rilparencel of 3x10⁶ cells/g-KW est'
- Older filing included detailed information about FDA Type B meeting and effect size requirement of '1.5 mL/min/1.73m²/year improvement'—removed in newer filing
- Older filing stated 'We have enrolled more than half of the patients required for the accelerated approval analysis'—removed in newer filing
- Older filing stated 'Updated guidance on the expected timing of the confirmatory readout will be provided in the first half of 2026'—newer filing provides specific timing: 'second half of 2029'
- Older filing included extensive REGEN-007 trial results and methodology—removed in newer filing
- Reworded:
- Older: 'clinical-stage biotechnology company' changed to newer: 'late-clinical-stage biotechnology company'
- Older: 'first-in-class, patented, proprietary autologous cell therapy' changed to newer: 'first-in-class, autologous cell therapy'
- Older: 'PROACT 1:' as subsection heading changed to newer: 'PROACT 1' with additional descriptive text
- Older: study protocol 'was amended in 1H 2024' changed to newer: study protocol 'has been amended' without specific date
- Older: eGFR ranges expressed as 'eGFR 20-30' changed to newer: 'eGFR between 20 and 30'
- Older: UACR expressed as 'less than 5,000 mg/g' and '300-5,000 mg/g' changed to newer: unified 'UACR between 300 and 5000 mg/g'
- Older: 'The primary objective is to assess the efficacy of up to two rilparencel injections (one in each kidney)' changed to newer: 'The primary objective of this study is to assess the efficacy of up to two rilparencel injections given three months apart and delivered into both kidneys'
- Older: 'surrogate endpoint for accelerated approval is eGFR slope, and the primary composite endpoint is...' changed to newer: 'The surrogate endpoint to support a potential accelerated approval of rilparencel is annualized eGFR slope'
- Older: 'We anticipate topline data readout of eGFR slope as the surrogate endpoint to support an application for accelerated approval in the second quarter of 2027' changed to newer: 'We anticipate topline data readout of the surrogate endpoint (eGFR slope) in the second quarter of 2027'
- Notes:
- Older filing text is truncated at end, cutting off discussion of Risk Factors and REGEN-007 section
- Newer filing text is also truncated, cutting off mid-sentence in Revenue section
- Comparison limited by textual truncation in both versions
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 6 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-040 buys · 6 sells ($1M) — 1 selling insider
- Last 180 days · read to 2026-10-040 buys · 6 sells ($1M) — 1 selling insider
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-20. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about PROK's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding PROK as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 7,657,778
- Reported value $15,621,867
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about PROK's institutional holders → See what each manager we track holds →
Short interest (FINRA)
PROK had 21,445,366 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for PROK because we do not hold a verified share count to divide it by. The reported figures above are unaffected.
- Reported short interest (shares) 21,445,366
- Prior settlement (shares) 20,737,263
- Reported change 3.41%
- Days to cover (reported) 19.04
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Bristol Myers Squibb (BMY)
- Novartis (NVS)
- Carisma Therapeutics (CARM)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare PROK vs…
PROKIDNEY CORP CLASS A is found in…
Frequently asked questions
What does PROKIDNEY CORP CLASS A (PROK) do?
ProKidney is a clinical-stage biotechnology company developing rilparencel, an autologous cell therapy designed to preserve kidney function in patients with advanced chronic kidney disease (CKD) and type 2 diabetes. By utilizing a patient's own kidney cells, the therapy aims to stabilize or attenuate the decline of the estimated glomerular filtration rate (eGFR) and delay the need for dialysis or transplantation without the requirement for long-term immunosuppression.
What sector is PROKIDNEY CORP CLASS A (PROK) in?
PROKIDNEY CORP CLASS A (PROK) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are PROKIDNEY CORP CLASS A's (PROK) competitors?
Notable peers of PROKIDNEY CORP CLASS A (PROK) include Bristol Myers Squibb, Novartis and Carisma Therapeutics. This peer set is informational only — not financial advice.
Is PROKIDNEY CORP CLASS A (PROK) overbought or oversold right now?
PROKIDNEY CORP CLASS A (PROK) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 48, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on PROK come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.